Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6099344rdf:typepubmed:Citationlld:pubmed
pubmed-article:6099344lifeskim:mentionsumls-concept:C0950124lld:lifeskim
pubmed-article:6099344lifeskim:mentionsumls-concept:C0346210lld:lifeskim
pubmed-article:6099344lifeskim:mentionsumls-concept:C0205064lld:lifeskim
pubmed-article:6099344lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:6099344lifeskim:mentionsumls-concept:C0733469lld:lifeskim
pubmed-article:6099344pubmed:issue6lld:pubmed
pubmed-article:6099344pubmed:dateCreated1985-4-29lld:pubmed
pubmed-article:6099344pubmed:abstractTextThe follow-up is presented for 13 patients with cervical intraepithelial neoplasia (CIN) grade II-III and vulvar intraepithelial neoplasia (VIN) grade III associated with papilloma virus infection, treated with human fibroblast interferon. Treatment consisted of 2-3 X 10(6) IU interferon per day injected intra- and peri-lesionally for five days per week for 2-3 weeks, with or without a cream topically applied at the dose of 1.2 X 10(6) IU/day X five days. Among the 13 patients with CIN and VIN, 7 complete (54%) and 2 partial regressions were observed. The duration of response appeared to be between 2 and 14 months. Fever, chills and fatigue were the tolerable side-effects. Our results indicate that treatment with interferon is active against CIN and VIN associated with papilloma virus infection.lld:pubmed
pubmed-article:6099344pubmed:languageenglld:pubmed
pubmed-article:6099344pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6099344pubmed:citationSubsetIMlld:pubmed
pubmed-article:6099344pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6099344pubmed:statusMEDLINElld:pubmed
pubmed-article:6099344pubmed:issn0250-0868lld:pubmed
pubmed-article:6099344pubmed:authorpubmed-author:RilkeFFlld:pubmed
pubmed-article:6099344pubmed:authorpubmed-author:PilottiSSlld:pubmed
pubmed-article:6099344pubmed:authorpubmed-author:GhioneMMlld:pubmed
pubmed-article:6099344pubmed:authorpubmed-author:De PaloGGlld:pubmed
pubmed-article:6099344pubmed:authorpubmed-author:StefanonBBlld:pubmed
pubmed-article:6099344pubmed:issnTypePrintlld:pubmed
pubmed-article:6099344pubmed:volume6lld:pubmed
pubmed-article:6099344pubmed:ownerNLMlld:pubmed
pubmed-article:6099344pubmed:authorsCompleteYlld:pubmed
pubmed-article:6099344pubmed:pagination523-7lld:pubmed
pubmed-article:6099344pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:meshHeadingpubmed-meshheading:6099344-...lld:pubmed
pubmed-article:6099344pubmed:year1984lld:pubmed
pubmed-article:6099344pubmed:articleTitleHuman fibroblast interferon in cervical and vulvar intraepithelial neoplasia associated with papilloma virus infection.lld:pubmed
pubmed-article:6099344pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6099344lld:pubmed